Vicore Pharma Holding AB is a clinical-stage pharmaceutical company headquartered in Stockholm, Sweden, specializing in treatments for rare lung diseases and scarring disorders. The company's principal focus is on unlocking the potential of angiotensin II type 2 receptor agonists (ATRAGs) to stabilize or reverse lung function decline. Its lead clinical program, buloxibutid (C21), is an orally available small molecule currently in Phase 2 development for idiopathic pulmonary fibrosis (IPF) and has received Orphan Drug and Fast Track designations from the US FDA. In addition to its traditional drug pipeline, Vicore is developing Almee, a digital therapeutic based on cognitive behavioral therapy to help patients manage the psychological burden of pulmonary fibrosis. The company operates primarily through research partnerships, clinical trials, and licensing arrangements, aiming to bring disease-modifying therapies to specialist lung-care markets globally.
Market capitalization, or "market cap", is the aggregate market value of a company represented in a dollar amount. Since it represents the “market” value of a company, it is computed based on the current market price (CMP) of its shares and the total number of outstanding shares.
Enterprise value (EV) measures a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt and any cash or cash equivalents on the company's balance sheet.
The enterprise value-to-revenue multiple (EV/R) is a measure of the value of a stock that compares a company's enterprise value to its revenue. EV/R is one of several fundamental indicators that investors use to determine whether a stock is priced fairly. The EV/R multiple is also often used to determine a company's valuation in the case of a potential acquisition. It's also called the enterprise value-to-sales multiple.
The enterprise value to earnings before interest, taxes, depreciation, and amortization ratio (EV/EBITDA) compares the value of a company—debt included—to the company's cash earnings less non-cash expenses. It's best to use the EV/EBITDA metric when comparing companies within the same industry or sector. Typically, when evaluating a company, an EV/EBITDA value below 10 is seen as healthy.
It follows the same logic as the EV/EBITDA indicator, but instead of EBITDA, EBIT is used, which considers non-cash D&A expenses in the company's operating result.
...and much more!